Managers / Q4 2019 · view latest →
SYQUANT CAPITAL SAS
CIK 0001766392 · 25 AVENUE KLEBER, PARIS, I0, 75116 · 0033142569307
Summary
Syquant Capital Sas reported $194M in U.S.-listed holdings across 16 positions for Q4 2019.
The portfolio is heavily concentrated: Audentes Therapeutics alone accounts for 23.7% of reported value.
Compared with Q3 2019, the fund opened 13 new positions and exited 14.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 88.7% · $172M
- Other · 10.3% · $20M
- Right · 1.0% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AUDENTES THERAPEUTICS INC | NEW | +767.5K | 767.5K | +$46M | $46M |
| MEDICINES CO | NEW | +505.0K | 505.0K | +$43M | $43M |
| TALLGRASS ENERGY LP | NEW | +972.4K | 972.4K | +$22M | $22M |
| CYEURCYPRESS SEMICONDUCTOR CORP | NEW | +782.5K | 782.5K | +$18M | $18M |
| TECH DATA CORP | NEW | +102.8K | 102.8K | +$15M | $15M |
| ARQULE INC | NEW | +619.8K | 619.8K | +$12M | $12M |
| ALLERGAN PLC | NEW | +55.5K | 55.5K | +$11M | $11M |
| RA PHARMACEUTICALS INC | NEW | +129.7K | 129.7K | +$6M | $6M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AUDENTES THERAPEUTICS INC | COM | 23.65% | $46M | 767.5K |
| 2 | MEDICINES CO | COM | 22.09% | $43M | 505.0K |
| 3 | TALLGRASS ENERGY LP | CLASS A SHS | 11.08% | $22M | 972.4K |
| 4 | CYEURCYPRESS SEMICONDUCTOR CORPhistory → | COM | 9.40% | $18M | 782.5K |
| 5 | TECH DATA CORP | COM | 7.60% | $15M | 102.8K |
| 6 | ARQULE INC | COM | 6.37% | $12M | 619.8K |
| 7 | ALLERGAN PLC | SHS | 5.46% | $11M | 55.5K |
| 8 | RA PHARMACEUTICALS INC | COM | 3.13% | $6M | 129.7K |
| 9 | TEEKAY OFFSHORE PARTNERS L P | PARTNERSHIP UN | 2.42% | $5M | 3.05M |
| 10 | DBV TECHNOLOGIES S A | SPONSORED ADR | 2.37% | $5M | 430.0K |
| 11 | OMNOVA SOLUTIONS INC | COM | 2.22% | $4M | 426.3K |
| 12 | WESCO AIRCRAFT HLDGS INC | COM | 2.05% | $4M | 361.0K |
| 13 | BRISTOL MYERS SQUIBB CO | RIGHT 99/99/9999 | 1.01% | $2M | 652.5K |
| 14 | TIFFANY & CO NEW | COM | 0.74% | $1M | 10.8K |
| 15 | TERRAFORM PWR INC | COM CL A | 0.20% | $391,000 | 25.4K |
| 16 | DIPLOMAT PHARMACY INC | COM | 0.19% | $377,000 | 94.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2026 | $447M | 38 | Jul 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q1 2026 | $640M | 40 | Apr 10, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $817M | 37 | Jan 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $348M | 17 | Oct 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $302M | 14 | Jul 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2025 | $141M | 14 | Apr 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $70M | 6 | Jan 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $27M | 5 | Oct 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $10M | 5 | Jul 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $64M | 6 | Apr 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $22M | 7 | Jan 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $255M | 9 | Oct 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $138M | 11 | Jul 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $43M | 7 | Apr 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $41M | 14 | Jan 17, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $165M | 25 | Oct 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $90M | 32 | Jul 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $195M | 35 | Apr 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $262M | 43 | Jan 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $164M | 42 | Oct 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $83M | 41 | Jul 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $386M | 53 | Apr 20, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $387M | 81 | Feb 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $196M | 62 | Oct 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $215M | 23 | Aug 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $407M | 18 | Apr 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $194M | 16 | Jan 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $365M | 17 | Oct 17, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $312M | 14 | Jul 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $258M | 15 | Apr 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $117M | 11 | Feb 4, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.